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A B S T R A C T
Depression in children and adolescents with epilepsy is common. Depression worsen quality of life in
epilepsy patients. Neurobiological, social, and iatrogenic factors may play a role in depressive disorder
development. We report a patient with partial epilepsy secondary to neonatal stroke, who developed
depressive disorder as a result of levetiracetam (LEV) treatment. Our report illustrates the possible
implication of iatrogenic factors in depression among epilepsy patients. However, recent data suggest
that LEV may be effective in case of affective disorders. We discuss the factors linking epilepsy with
depression. Because of its high incidence and its multiple physiopathologic factors, psychiatric
comorbidity should be always assessed in pediatric epileptic patients.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Drugs that act on the brain commonly affect multiple areas and
brain functions in addition to those that are primarily targeted.
While this attribute can be advantageous, and as such is often
employed in the treatment of migraine, bipolar disorders and some
other CNS impairments, it also may cause certain adverse effects.
Levetiracetam (LEV) is a new AED reported to have a high degree of
tolerability in both adult and children patients with epilepsy.
Moreover, pilot studies have recently been completed to explore the
potential utility of LEV in the treatment of affective disorders, and
both preclinical data1 and clinical trials suggest that it may be an
effective treatment for bipolar spectrum disorders.2 At the same
time, some studies reported that adverse behavioural and psychia-
tric events may occur in patients with epilepsy, who receive LEV. In
pivotal randomized controlled trials, 13.3% of levetiracetam-treated
epilepsypatients reportedbehavioural symptoms, such as agitation,
hostility, anxiety, apathy, emotional lability, as comparedwith 6.2%
of placebo patients.3,4 To our best knowledge, we are the ﬁrst to
report a major depressive disorder induced by LEV in a pediatric
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A 5-year-old boy was ﬁrst diagnosed with epilepsy at age of 3
years. He had no familial history. He experienced neonatal cerebral
infarction which led to right hemiparesis and partial epilepsy.
Several antiepileptic drugs were tried, starting with valproate. An
addition of oxcarbazepine caused rash. Therefore, oxcarbazepine
was replaced with lamortigine. Finally, because seizures persisted,
LEV replaced valproate in addition to lamotrigine. With the latter
combination, a striking remission of attacks was observed. Three
weeks after the start of LEV therapy, the patient developed lack of
appetite (evident as reduced food intake) and insomnia with
difﬁculties initiating sleep. In addition, the parents observed
fatigue, irritability, loss of interest for games, and loss of reaction to
pleasurable stimuli. He stopped playing with sibling and did not
show interest in any activities. Instead, he spent long time lying in
bed. Furthermore, according to his mother, he experienced a
diminished ability to concentrate. Finally, aggressive behaviours
were observed at school. Four weeks after the onset of the
symptoms, he was admitted to our department. LEV was discon-
tinued and clobazam was started. Two weeks later, the symptoms
of depression completely disappeared, and the patient returned to
previous functioning.
3. Discussion
Weare the ﬁrst to report LEV-induced depression in a childwith
epilepsy. Previously, the patient never experienced any psychiatricvier Ltd. All rights reserved.
C. Tamarelle et al. / Seizure 18 (2009) 235–236236or behavioural symptoms. He developed major depressive episode
according to the DSM (Diagnostic and Statistical Manual) IV-R
criteria. The onset of depressive symptoms was observed 3 weeks
after the start of LEV although the seizures were under control by
the AED. Interestingly, he returned to his previous state 2 weeks
after the discontinuation of LEV without time to start psychother-
apy. We did not ﬁnd any life event which could explain the
symptoms of depression. Taking into the account all thementioned
details, we concluded that major depressive episode in our patient
was a result of LEV treatment.
Children with epilepsy are more vulnerable to psychiatric
disorders than general population. Furthermore, the incidence of
depression among pediatric patients with epilepsy is higher than
in other chronic childhood diseases. Several factorsmay contribute
to emotional symptoms in the speciﬁc disorder of epilepsy. These
inﬂuences include CNS variables (e.g., effects of seizures, con-
comitant CNS conditions giving rise to seizures, and medications),
as well as psychosocial factors (e.g., the stigma of having seizures).
Experimental studies have shown that depression develops under
conditions of animal models of absence epilepsy (particularly in
the genetic absence epilepsy rat from Strasbourg5), as well as
temporal lobe epilepsy.6,7
AED may also be involved in pathophysiology of mood
disorders in epileptic patients. GABAergic drugs exhibit negative
effect on mood while carbamazepine and lamotrigine appear to
inﬂuence it positively.8,9 The barbiturates, vigabatrin and topir-
amate show greater associationswith the occurrence of depressive
symptoms than other antiepileptic drugs, presenting in up to 10%
of all patients, but evenmore so in susceptible patients. Phenytoin,
ethosuximide, carbamazepine, oxcarbazepine, gabapentin, valpro-
ate, pregabalin and lamotrigine are all associatedwith low risks for
depression (<1%), and several of these antiepileptic drugs seem to
have a positive effect on mood.9
Regarding LEV treatment, there are several reports on beha-
vioural and psychiatric side effects. The most frequent complaints
have been irritability, nervousness, hostility and anxiety.3,4 A
medically and psychiatrically healthywoman developed symptoms
consistent with major depressive disorder while she was underLEV.10 At the same time, several studies reported therapeutic effects
of LEV on anxiety and/or depression.2,11
In conclusion, the reported case illustrates the importance of
careful monitoring of behavioural effects of AED. To our knowledge,
this is the ﬁrst reported case of depression induced by levetiracetam
in children. Depression in childhood is frequently underdiagnosed.
Because of its high incidence and its multiple physiopathologic
factors, psychiatric comorbidity should be always assessed in
pediatric epileptic patients.
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